Pfizer (NYSE:PFE) CEO Ian Read has gone about remaking the pharma-based conglomerate into a leaner, more focused company. In advance of reporting second-quarter results, Pfizer announced a new re-organization.
Pfizer management has used the terms "innovative" business and "value" business on previous conference calls, so while this shake-up isn't a surprise, the groupings are given that we have three units instead of two. Innovative 1 is a broad swath of branded pharma products, while Innovative 2 is vaccines, oncology, and consumer health care. Finally, there is Value, which is all established --  e.g., no longer patent-protected products -- or those products losing patent protection by 2015.

In this video, health care analyst David Williamson discusses what these events mean for investors in Pfizer and whether a bigger break-up of the company is at hand.

Follow David on Twitter: @MotleyDavid.

David Williamson owns shares of Pfizer and Zoetis. Follow David on Twitter: @MotleyDavid.

The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.